Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Biological: filgrastim
Drug: amifostine trihydrate
Drug: cisplatin
Drug: cyclophosphamide
Drug: vincristine sulfate
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2003-07-09

Last Posted Date: 2012-11-07

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 94

Registration Number: NCT00003211

Locations: 🇺🇸
Texas Children's Cancer Center, Houston, Texas, United States
🇦🇺
Royal Children's Hospital, Parkville, Victoria, Australia
🇦🇺
Children's Hospital at Westmead, Westmead, New South Wales, Australia

and more 1 locations

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

Phase 2

Completed

Conditions: Multiple Myeloma
Plasma Cell Myeloma

Interventions: Biological: filgrastim
Drug: cyclophosphamide
Drug: dexamethasone
Drug: melphalan
Drug: thalidomide
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-07-09

Last Posted Date: 2018-08-09

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 104

Registration Number: NCT00064337

Locations: 🇺🇸
Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States
🇺🇸
Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
🇺🇸
St. Peter's Hospital, Helena, Montana, United States

and more 31 locations

Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2003-07-08

Last Posted Date: 2013-08-02

Lead Sponsor: Institute of Cancer Research, United Kingdom

Target Recruit Count: 6000

Registration Number: NCT00002582

Locations: 🇬🇧
Cancer Research Campaign Trials Unit-Birmingham (CRCTU), Birmingham, England, United Kingdom
🇬🇧
Beatson Oncology Centre, Glasgow, Scotland, United Kingdom

Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-06-27

Last Posted Date: 2012-12-11

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 89

Registration Number: NCT00003352

Locations: 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
Veterans Affairs Medical Center - Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 163 locations

Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-06-20

Last Posted Date: 2010-05-13

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00025545

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

Phase 2

Completed

Conditions: Neutropenia
Sarcoma

Interventions: Biological: filgrastim
Drug: amifostine trihydrate
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: topotecan hydrochloride
Drug: vincristine sulfate
Procedure: conventional surgery
Radiation: low-LET cobalt-60 gamma ray therapy
Radiation: low-LET electron therapy
Radiation: low-LET photon therapy

First Posted Date: 2003-06-18

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 130

Registration Number: NCT00002643

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Medical City Dallas Hospital, Dallas, Texas, United States
🇺🇸
Long Beach Memorial Medical Center, Long Beach, California, United States

and more 46 locations

Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-06-12

Last Posted Date: 2012-02-20

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Registration Number: NCT00018954

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇪🇬
National Cancer Institute of Egypt, Cairo, Egypt
🇮🇳
Kidwai Memorial Institute of Oncology, Bangalore, India

and more 2 locations

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2003-06-06

Last Posted Date: 2017-07-02

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 33

Registration Number: NCT00062036

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Acute Undifferentiated Leukemia
B-cell Adult Acute Lymphoblastic Leukemia
B-cell Childhood Acute Lymphoblastic Leukemia
L1 Adult Acute Lymphoblastic Leukemia
L1 Childhood Acute Lymphoblastic Leukemia
L2 Adult Acute Lymphoblastic Leukemia
L2 Childhood Acute Lymphoblastic Leukemia
Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia

Interventions: Drug: allopurinol
Drug: cyclophosphamide
Drug: daunorubicin hydrochloride
Drug: vincristine sulfate
Drug: dexamethasone
Drug: asparaginase
Biological: filgrastim
Drug: imatinib mesylate
Drug: methotrexate
Drug: cytarabine
Drug: trimethoprim-sulfamethoxazole
Drug: mercaptopurine
Drug: leucovorin calcium
Biological: alemtuzumab
Drug: acyclovir
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-06-06

Last Posted Date: 2022-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 302

Registration Number: NCT00061945

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: celecoxib
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: vinblastine sulfate
Drug: vincristine sulfate
Procedure: conventional surgery
Radiation: radiation therapy
Drug: MESNA
Drug: Filgrastim

First Posted Date: 2003-06-06

Last Posted Date: 2019-02-15

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 38

Registration Number: NCT00061893

Locations: 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, Huntington, West Virginia, United States

and more 98 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy